

1 Using clustering of genetic variants in Mendelian
2 randomization to interrogate the causal pathways
3 underlying multimorbidity

4 Xiaoran Liang^{*a} Ninon Mounier^a, Nicolas Apfel^b, Sara Khalid^c, Timothy
5 M Frayling^{a,d}, and Jack Bowden^a, on behalf of the GEMINI Consortium

6 ^aGenetics of Complex Traits, Exeter Medical School, University of Exeter, Exeter, UK

7 ^bDepartment of Economics, University of Southampton, Southampton, UK

8 ^cCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and
9 Musculoskeletal Sciences, University of Oxford, Oxford, UK

10 ^dFaculty of Medicine, Department of Genetic Medicine and Development, CMU, Geneva,
11 Switzerland

November 7, 2023

12 *correspondence: x.liang2@exeter.ac.uk

Abstract

Mendelian randomization (MR) is an epidemiological approach that utilizes genetic variants as instrumental variables to estimate the causal effect of a modifiable but likely confounded exposure on a health outcome. This paper investigates an MR scenario in which different subsets of genetic variants identify different causal effects. These variants may aggregate into clusters, and such variant clusters are likely to emerge if they affect the exposure and outcome via distinct biological pathways. In the framework of multi-outcome MR, where a common risk factor causally impacts several disease outcomes simultaneously, these variant clusters can reflect the heterogeneous effects this shared risk factor concurrently exerts on all the diseases under examination. This, in turn, can provide insights into the disease-causing mechanisms underpinning the co-occurrence of multiple long-term conditions, a phenomenon known as multimorbidity. To identify such variant clusters, we adapt the general method of Agglomerative Hierarchical Clustering (AHC) to the summary data MR setting, enabling cluster detection based on the variant-specific causal estimates, using only genome-wide summary statistics. In particular, we tailor the method for multi-outcome MR to aid the elucidation of the potentially multifaceted causal pathways underlying multimorbidity stemming from a shared risk factor. We show in various Monte Carlo simulations that our ‘MR-AHC’ method detects variant clusters with high accuracy, outperforming the existing multi-dimensional clustering methods. In an application example, we use the method to analyze the causal effects of high body fat percentage on a pair of well-known multimorbid conditions, type 2 diabetes (T2D) and osteoarthritis (OA), discovering distinct variant clusters reflecting heterogeneous causal effects. Pathway analyses of these variant clusters indicate interconnected cellular processes underlying the co-occurrence of T2D and OA; while the protective effect of higher adiposity on T2D could possibly be linked to the enhanced activity of ion channels related to insulin secretion.

Keywords: Mendelian randomization; clustering analysis; multimorbidity; robust MR; hierarchical clustering; heterogeneous causal effects.

43 Introduction

44 Mendelian randomization (MR) is a widely used method in epidemiology that leverages
45 genetic variants (usually in the form of single nucleotide polymorphisms, SNPs) as in-
46 strumental variables (IV) for estimating the causal effect of a potentially confounded
47 exposure on an outcome [1, 2]. If a genetic variant is sufficiently associated with the
48 exposure, independent of possible confounders of the exposure-outcome relationship, and
49 affects the outcome only through the exposure, then it is a valid instrument for assess-
50 ing causality [3]. With further parametric assumptions, for example that relationships
51 between all variables are additive and linear, and all variants included as instruments
52 encode a single homogeneous causal effect from the exposure to the outcome, then the
53 causal parameter of interest can be estimated using simple meta-analytic methods based
54 on genome-wide summary statistics [4–6]. In this setting, all the variant-specific causal
55 estimates are expected to target the same, true causal effect, and their ‘ratio’ estimates
56 (derived as the ratio of the variant-outcome to variant-exposure association), from which
57 the overall meta-analysis is performed, should vary by sampling error alone [7, 8]. Excess
58 ‘heterogeneity’ amongst the ratio estimates is therefore a sign that one or more of the
59 assumptions has been violated [9].

60

61 A major source of excess heterogeneity is undoubtedly *horizontal pleiotropy*, the phe-
62 nomenon whereby a variant affects multiple traits and therefore is associated with the
63 outcome through pathways other than via the exposure [9, 10]. This has been extensively
64 studied with improved methods for pleiotropy detection [8, 11] and robust estimation [5,
65 12, 13]. Violation of the causal effect homogeneity assumption, has, by contrast, been far
66 less researched, despite this being a plausible feature of many analyses. For example, it is
67 suspected that general adiposity, which is often proxied by a single trait like body mass
68 index (BMI), exerts a heterogeneous causal effect on type 2 diabetes (T2D) depending
69 on the location of the adipose tissue in the body (e.g. if it is peripheral or visceral) [14].
70 In this case, variants associated with different physiological aspects of the exposure may

71 target distinct causal effects.

72

73 In the presence of excess heterogeneity from both sources, the genetic variants can be
74 grouped into distinct clusters, such that all variants in each cluster indicate the same
75 effect. Several studies have explored variant clusters in the MR framework. It is well
76 recognized that it is impossible to discern whether each cluster embodies genuine causal
77 mechanisms between the exposure and outcome, or is formed due to pleiotropic pathways,
78 without further domain knowledge or modelling assumptions. Therefore, overdispersion
79 caused by both sources can be summarized under an umbrella term such as “clustered
80 heterogeneity”, as proposed by Foley et al. [15], or “mechanistic heterogeneity” by Iong
81 et al. [16].

82

83 In this paper, we propose a method to identify variant clusters under mechanistic hetero-
84 geneity, building upon the Agglomerative Hierarchical Clustering (AHC) method devel-
85 oped by Apfel and Liang [17] in the field of econometrics for IV selection. We adapt the
86 method to the summary-data MR setting, hence referring to it as “MR-AHC”, to group
87 variants based on their ratio estimates using genome-wide summary statistics. More no-
88 tably, we have tailored the method to the multi-outcome MR setting, in which a shared
89 exposure causally impacts several disease outcomes simultaneously. This extension is
90 specially crafted for investigating the causal mechanisms underpinning multimorbidity,
91 which refers to the co-existence of two or more long-term conditions in one individual [18].

92

93 A substantial and growing proportion of the adult population is affected by multimor-
94 bidity, and it has been recognized as a global priority for health research [19, 20]. It is
95 therefore important to comprehend the underlying disease-causing pathways. Numerous
96 studies have identified common risk factors associated with a broad range of conditions.
97 New methods have also been introduced for identifying these factors [21]. However,
98 such shared risk factors are often complex traits and may exert heterogeneous influences
99 on diseases through multifaceted mechanisms. For example, obesity, one of the most

100 well-established risk factors contributing to various forms of multimorbidity [22, 23], is
101 recognized to impact diseases through a variety of distinct pathways [14, 24].

102

103 Given the multitude of potential causal pathways stemming from a common risk fac-
104 tor, particularly in the case of complex traits like obesity, to enable effective clinical
105 prevention and intervention, it is necessary to elucidate the mechanisms through which
106 this common risk factor induces the co-occurrence of the conditions. A starting point can
107 be identifying the variant clusters associated with diverse causal effects within a multi-
108 outcome MR framework. To illustrate this, consider the hypothetical example depicted
109 in Figure 1. Here, variants linked to the exposure X are divided into three groups (G_1 to
110 G_3), as they influence the two disease outcomes Y_1 and Y_2 through three different aspects
111 of the exposure X (denoted by X_1 to X_3) that might not be easy to measure directly.
112 Among the three groups, G_1 is associated with an increasing effect on Y_1 but a protective
113 effect against Y_2 , and G_3 indicates an increasing effect on Y_2 but no effect on Y_1 . Only
114 the group G_2 corresponds to pathways through which the shared risk factor increases the
115 risk of both diseases. Therefore, identifying variant clusters can unveil the potentially
116 heterogeneous causal effects, and subsequently shed light on the mechanisms linking the
common risk factor to the co-occurrence of the conditions.




Figure 1: Left: Multi-outcome MR involving two disease outcomes and a common risk factor; right: clusters formed by the variants associated with the common exposure, which reflect heterogeneous causal pathways.

117

118 Several clustering approaches have been proposed within the MR framework to group ge-
119 netic variants based on their causal estimates, such as MR-Clust [15] and MR-PATH [16].
120 However, these methods are primarily tailored to settings involving a single exposure and
121 a single outcome, making them less suitable for handling the complexities of multimor-
122 bidity, as they lack multi-dimensional clustering options. On the other hand, methods
123 such as NAvMix [25] do allow for multi-dimensional clustering of genetic variants, but
124 are not inherently rooted in the MR framework, since they group variants based on their
125 direct variant-trait associations, rather than causal estimates. This may limit their utility
126 for causal inference. The mclust method [26] does permit multi-dimensional clustering
127 using causal estimates, but we show that the method's accuracy can be sub-optimal. In
128 contrast, our MR-AHC method allows for multi-dimensional causal clustering based on
129 MR estimates, whilst achieving a high clustering accuracy, which we have demonstrated
130 in extensive Monte Carlo simulations.

131

132 We apply MR-AHC to investigate the causal effects of body fat percentage (BFP), as
133 a shared risk factor, on a pair of multimorbid conditions, T2D and osteoarthritis (OA).
134 Our analysis identifies four variant clusters indicating heterogeneous effects on both con-
135 ditions. To provide insights into the underlying causal pathways, we conducted com-
136 prehensive gene-set analyses on the clusters, combining evidence from both canonical
137 pathway analyses and gene-set Phenome-wide association analyses (PheWAS). While the
138 clustering results cannot directly label a cluster as signifying genuine mechanisms or
139 pleiotropic pathways, we show how post-clustering analyses may enable this distinction.
140 Our findings on the cluster associated with increasing risks of both conditions indicate
141 shared pathways underpinning the co-occurrence of T2D and OA through interconnected
142 cellular processes related to gene expression transcription and cellular responses to stim-
143 uli. We provide further evidence using cluster-specific MR for the unifying pathway from
144 obesity to the T2D-OA multimorbidity through elevated oxidative stress. Another cluster
145 exhibits a protective effect against T2D, with integrated canonical pathway and PheWAS
146 evidence supporting a possible mechanism involving enhanced activity of the ion chan-

147 nels related to insulin secretion. This might be linked to elevated levels of high-density
148 lipoprotein cholesterol (HDL-C) associated with smaller waist-to-hip ratios.

149 Results

150 The MR-AHC method for clustering genetic variants in summary- 151 data Mendelian randomization

152 We assume the following summary statistics for J genetic variants involved in an MR
153 investigation: the variant-exposure association estimate $\hat{\gamma}_j$, and the variant-outcome as-
154 sociation estimate $\hat{\Gamma}_j$, where $j = 1, \dots, J$. In an MR setting with a common exposure and
155 multiple P outcomes, $\hat{\Gamma}_j$ is the vector of the P variant-outcome associations. We main-
156 tain the assumption that the variant-exposure associations are measured from a sample
157 independent from all the variant-outcome association samples, but overlap between the
158 outcome samples is allowed. We also assume that all the genetic variants are themselves
159 mutually uncorrelated (i.e. not in linkage disequilibrium). The causal estimates of the
160 exposure on the P outcomes using only variant j as instrument (i.e. the ratio estimates)
161 can then be obtained as the P -dimensional vector $\hat{\beta}_j = \hat{\Gamma}_j / \hat{\gamma}_j$. Let $\hat{\Sigma}_j$ be an estimate of
162 the covariance matrix of $\hat{\beta}_j$.

163

164 We propose MR-AHC, a two-step procedure with $\{\hat{\beta}_j, \hat{\Sigma}_j\}_{j=1}^J$ as inputs, to group genetic
165 variants indicating the same causal effects, or in other words, having similar observed ratio
166 estimates $\hat{\beta}_j$, into the same cluster. We illustrated the method with a simple hypothetical
167 example, shown in Figure 2. For ease of illustration, we consider the case with a single
168 outcome, but the same procedure applies generally with multiple outcomes. The first
169 step of the method, the merging step, is illustrated in the left panel of Figure 2. It shows
170 a situation with six variants that form three clusters (one of them comprised of a single
171 variant). The dotted lines at β_1 and β_2 are the true heterogeneous causal effects from the
172 exposure to the outcome, and the circles above the real line denote the variant-specific ra-
173 tio estimates. The differences in the size of the circles reflect the fact that summary data

174 estimates exhibit varying degrees of uncertainty. In the explanation below, we refer to
 175 these estimates and their corresponding variants by the numbers 1 to 6, from left to right.

176

177 In the initialization step of the merging process (Step 0 in the illustration), each variant-
 178 specific estimate has its own cluster. Next, we merge the two estimates which are closest
 179 in terms of their weighted squared Euclidean distance, i.e. those estimated with Variant
 180 3 and 4 (the two red circles). These two estimates are merged into one cluster and we
 181 now have five clusters left. We re-calculate the pairwise distances with the five clusters
 182 and merge the closest two into a new cluster. We continue with this procedure until step
 183 5 where all variants are in a single cluster.




Figure 2: Illustration of the MR-AHC method for a hypothetical example adapted from Apfel and Liang [17]. Left panel: Ward’s algorithm defines a clustering path. Right panel: A downward testing procedure is applied until the step-specific heterogeneity statistics can not be rejected at a specified threshold.

184 By the end of the merging step, we have generated a clustering path. Along each step of
 185 the path, the number of clusters, denoted by \mathcal{K} , varies from $\mathcal{K} = 1$ to $\mathcal{K} = J$ by incre-
 186 ments of 1. Next, in the second step of MR-AHC, we re-trace the clustering path to select
 187 the optimal value of \mathcal{K} using a downward testing procedure, operates as follows: starting
 188 from the largest cluster containing all variants, apply Cochran’s Q test [27] to examine
 189 the degree of heterogeneity of all the ratio estimates by calculating the test statistic and
 190 comparing it with a pre-specified significance threshold. If the null hypothesis of “no ex-
 191 cess heterogeneity” gets rejected, then move to the next level of the clustering path and
 192 apply the Q test to all the sub-clusters on that level. We repeat this process until reach-

193 ing a level where no sub-cluster heterogeneity statistic rejects at the given significance
194 threshold. In our illustrative example, we would expect the downward testing procedure
195 to re-trace from step 5 to step 3 of the clustering path, thus determining three groups
196 formed by Variants 1-2, Variants 3-5, and Variant 6 alone.

197

198 In the original AHC algorithm proposed by Apfel and Liang [17], the inputs are essen-
199 tially just the ratio estimates $\hat{\beta}_j$, hence the clustering objects are treated as non-random
200 fixed data points. MR-AHC adjusts the algorithm to take into account the uncertainty
201 of $\hat{\beta}_j$ by incorporating the covariance matrix $\hat{\Sigma}_j$ into the weighted squared Euclidean
202 distance in the merging process. We show in Appendix A that this distance between two
203 clusters is essentially the Wald statistic for testing the null hypothesis that “the two clus-
204 ters indicate the same causal effect”. Therefore, merging two clusters with the smallest
205 distance can be interpreted as merging two clusters with the highest similarity in their
206 cluster-specific causal effects.

207

208 In terms of the covariance matrix estimate $\hat{\Sigma}_j$, we show in Appendix A that if all the
209 outcome samples are non-overlapping and/or the phenotypic correlations between the
210 outcome traits are zero, then all the ratio estimates of a given variant are uncorrelated.
211 In this case, all the covariance terms are zero and $\hat{\Sigma}_j$ is just a diagonal matrix with the
212 non-zero entries being the variances of the ratio estimates, which can be easily estimated
213 from the GWAS summary statistics. If the covariances are non-zero, we show that $\hat{\Sigma}_j$
214 can be estimated via linkage disequilibrium (LD) score regression [28] and seamlessly
215 incorporated into the analysis.

216

217 In the downward testing procedure, following the recommendation in Belloni et al. [29],
218 we define the threshold p-value for the Q test as $\zeta = 0.1/\log(n)$ where n is the sample
219 size. We prove in Appendix B that this threshold p-value results in a consistent cluster-
220 ing procedure. That is, as n increases, the probability of correctly identifying all true
221 members of each cluster tends to 1. If the exposure and outcome samples are of different

222 sizes, we recommend using the sample size of the smallest outcome sample. For binary
223 outcomes, an effective sample size can be approximated with the number of cases and
224 controls, see Han and Eskin [30].

225

226 MR-AHC does not require pre-specification of the number of clusters. It can also easily
227 identify a “null cluster” and a “junk cluster”, following the terminology of Foley et al.
228 [15], which refer to, respectively, the cluster identifying a zero causal effect, and the clus-
229 ter containing variants not assigned to any detected clusters. Specifically, we conduct a
230 post-clustering Wald test on each cluster-specific causal estimate for the null hypothesis
231 of a zero causal effect using $\zeta = 0.1/\log(n)$ as the threshold significance p-value. For the
232 junk cluster, we simply classify all variants that do not fit into any other clusters as junk
233 variants. To further improve the clustering accuracy of MR-AHC, we also extend the
234 basic algorithm illustrated above to an outlier-robust version, to correct for the outliers
235 in the ratio estimates, see the method section for details.

236 **Simulation results**

237 We conduct Monte Carlo simulations to evaluate the performance of the MR-AHC
238 method in detecting variant clusters and estimating the causal effects in various settings
239 that mimic the multimorbidity scenarios we are interested in, which involve a shared
240 exposure causally affecting multiple outcome conditions. We consider 12 simulation de-
241 signs, where the number of outcomes is either $P = 2$ or $P = 3$, the number of substantive
242 variant clusters is either $K = 1$ or $K = 4$, and the sample correlation between the out-
243 comes is either $\rho = 0$, $\rho = 0.2$ or $\rho = 0.7$ (see the method section for a detailed definition
244 of ρ). In all designs, we have $J = 100$ SNPs with 10 designated as true ‘junk’ variants.


245

246 The two classes of scenarios stratified by the number of variant clusters are illustrated in
247 Figure 3. The directed acyclic graph (DAG) in Panel (a) illustrates the data generation
248 process when there are four substantive clusters and one noise cluster. Multiple outcomes
249 (two or three) are represented by the single notation Y . Variant clusters are formed due


250 to differential sub-components of the exposure, denoted by X_1 to X_5 . Variant Cluster 1
251 and X_1 represent a correlated pleiotropy pathway, and Clusters 2 to 4 correspond to gen-
252 uine heterogeneous causal mechanisms from the exposure to the outcomes. The scatter
253 plot on the right of Panel (a) is based on a representative simulated dataset of the two-
254 outcome case. We also examine the performance of the method when there is actually no
255 mechanistic heterogeneity, i.e. there is only one real cluster and one noise cluster. The
256 design is shown by a DAG and representative dataset in Figure 3 Panel (b). The arrow
257 from X_1 to Y is absent, meaning that the only substantive cluster is also a null cluster
258 and there is no causal effect between the exposure and the outcomes. See the method
259 section for a detailed design specification.

260

261 We compare MR-AHC with two other multi-dimensional clustering approaches. The
262 first is the mclust algorithm [26], a general clustering method that accommodates the
263 utilization of ratio estimates as inputs. We select this method as it is one of the most
264 widely used clustering method based on Gaussian mixture models [26]. We implement
265 mclust in two ways: the basic setting without a noise component, and the setting incor-
266 porating a Poisson noise component. An initial value of the proportion of noise variants
267 is required, and we set this value favourably as 10% which is the ground truth. The
268 second method, NAvMix, proposed by Grant et al. [25], groups genetic variants based
269 on the variant-trait associations instead of the ratio estimates. We choose this method
270 for comparison as it is also motivated by elucidating the biological mechanisms that can
271 possibly be revealed by the patterns of the genetic variants associated with various traits.
272 We employed two sets of input data for NAvMix: the variant-trait associations, as ini-
273 tially proposed; and the ratio estimates as in MR-AHC. Similar to mclust, we set the
274 initial proportion of noise variants for NAvMix at 10%. For these two methods, cluster
275 membership is assigned based on the highest probability. As a general clustering method
276 for mechanistic heterogeneity, MR-AHC also works in the one-outcome case. We com-
277 pare MR-AHC with MR-Clust [15], a popular method for conducting one-dimensional
278 clustering based on ratio estimates, see Table S4 in Appendix D.



(a) Simulation designs with 4 substantive variant clusters.



(b) Simulation designs with 1 substantive variant cluster.

Figure 3: Directed acyclic graphs (DAG) of the data generation process and scatter plots of representative simulated data (with two outcomes) of the simulation designs with different numbers of variant clusters.

279 We report the following statistics from the simulations for each approach: the number of
 280 substantive clusters detected by the methods ("*#clusters*"); the Rand index which mea-
 281 sures the similarity between the true clustering structure and the detected clusters for the
 282 substantives clusters ("*Rand index*"); the number of variants classified into the junk clus-
 283 ter ("*#junk variants*"); the number of true noise variants classified by the methods as junk
 284 ("*correct junk*"); the mean absolute error ("*MAE*") and the mean squared error ("*MSE*").
 285 For simulation designs with one substantive cluster indicating zero causal effects, we


286 additionally report the frequency of correctly identifying the null cluster ("*Freq.null*").

287 Definitions of the statistics can be found in the method section.

288

289 For scenarios involving non-zero outcome sample correlations, since the GWAS results
290 typically lack a direct estimate for the correlation, we initially apply all methods treating
291 the correlation ρ as zero. The two-outcome simulation results are presented in Figure 4
292 and Table 1. Across all settings, MR-AHC consistently demonstrates high accuracy in
293 identifying the number of clusters, aligning closely with the ground truth in both mean
294 and median assessments. In the boxplot of MR-AHC (Panel (a) of Figure 4), all the
295 quantiles are concentrated around the median, showing that the method consistently di-
296 vides variants into the correct number of clusters with little fluctuation. By comparison,
297 both settings of mclust tend to underestimate the number of clusters when there are four
298 true clusters and overestimate it when only one substantive cluster exists. The NAvMix
299 method, employing two different sets of input, also exhibits a tendency to underestimate
300 the number of clusters when $K = 4$. While it successfully identifies one cluster when
301 $K = 1$ with low outcome correlations, it overestimates the cluster number when the out-
302 come correlation is high ($\rho = 0.7$). In line with the cluster number results, MR-AHC
303 performs very well in terms of grouping the variants correctly, as measured by the Rand
304 index. It consistently achieves Rand indices close to 1, significantly outperforming all
305 other approaches in all settings. One potential drawback of MR-AHC is its tendency
306 to assign slightly more noise variants to the “junk” cluster than the true count, but the
307 number of true noise variants selected as junk of MR-AHC is only marginally lower than
308 that of mclust with the noise component, outperforming all other approaches. Regarding
309 estimation bias, both MR-AHC and NAvMix with ratio estimates input exhibit compara-
310 ble MAE and MSE in general, both of which are smaller than those of other methods in
311 most of the settings. For scenarios where $K = 1$, MR-AHC accurately identifies the null
312 cluster with frequencies close to 1. The two variations of NAvMix also exhibit high accu-
313 racy in this aspect, although this accuracy diminishes for NAvMix with ratio estimates
314 when the outcome correlation is high.

Panel (a) – The number of detected substantive clusters.



Panel (b) – Rand index for variants in the substantive clusters.




Figure 4: Two outcomes – boxplots for the number of detected substantive clusters and Rand index with different cluster numbers ($K = 4$ or $K = 1$) and outcome correlations ($\rho = 0$, $\rho = 0.2$ and $\rho = 0.7$). All methods are conducted treating the outcome correlations as 0. The dotted horizontal lines represent the true values. "mclust noise" stands for the mclust algorithm with a noise component, and "NAvMix ratio" for the NAvMix method with ratio estimates as input. Results are based on 1000 replications.

Table 1: Simulation results for designs with two outcomes. All methods are conducted treating the outcome correlations as 0. "*mclust noise*" stands for the *mclust* algorithm with a noise component, and "*NAvMix ratio*" for the *NAvMix* method with ratio estimates as input. Statistics are calculated as the mean over 1000 replications.

	MR-AHC	<i>mclust</i>	<i>mclust noise</i>	<i>NAvMix</i>	<i>NAvMix ratio</i>
Two outcomes, K = 4, correlation = 0					
# clusters	4.196	3.716	2.964	3.018	2.307
Rand index	0.917	0.757	0.737	0.615	0.710
# junk variants	10.966	0.000	7.726	6.517	4.080
# correct junk	6.975	0.000	7.134	1.446	3.951
MAE	0.088	0.120	0.123	0.162	0.106
MSE	0.030	0.041	0.041	0.052	0.035
Two outcomes, K = 4, correlation = 0.2					
# clusters	4.207	3.665	2.933	3.130	2.254
Rand index	0.915	0.744	0.725	0.630	0.694
# junk variants	10.916	0.000	7.835	6.930	3.999
# correct junk	7.031	0.000	7.234	1.493	3.906
MAE	0.088	0.118	0.122	0.153	0.101
MSE	0.030	0.039	0.040	0.048	0.032
Two outcomes, K = 4, correlation = 0.7					
# clusters	4.229	3.652	3.754	3.649	2.202
Rand index	0.918	0.784	0.835	0.684	0.677
# junk variants	10.993	0.000	8.044	5.347	3.925
# correct junk	7.144	0.000	7.433	1.302	3.844
MAE	0.089	0.091	0.088	0.119	0.087
MSE	0.029	0.027	0.027	0.035	0.024
Two outcomes, K = 1, correlation = 0					
# clusters	1.026	2.211	1.312	1.000	1.001
Rand index	0.947	0.887	0.895	0.818	0.818
# junk variants	10.194	0.000	8.211	0.000	0.000
# correct junk	7.703	0.000	7.073	0.000	0.000
MAE	0.012	0.020	0.015	0.017	0.017
MSE	0.000	0.004	0.001	0.000	0.000
Freq.null	0.955	0.726	0.767	0.998	0.997
Two outcomes, K = 1, correlation = 0.2					
# clusters	1.019	2.226	1.297	1.009	1.007
Rand index	0.949	0.881	0.893	0.816	0.816
# junk variants	10.275	0.000	8.438	0.058	0.060
# correct junk	7.833	0.000	7.199	0.009	0.008
MAE	0.012	0.021	0.015	0.017	0.018
MSE	0.000	0.004	0.001	0.000	0.001
Freq.null	0.965	0.724	0.791	0.996	0.990
Two outcomes, K = 1, correlation = 0.7					
# clusters	1.025	2.221	1.296	1.883	1.881
Rand index	0.948	0.910	0.924	0.546	0.545
# junk variants	9.685	0.000	9.458	29.057	27.936
# correct junk	7.995	0.000	8.323	5.099	5.020
MAE	0.013	0.019	0.014	0.026	0.113
MSE	0.000	0.003	0.001	0.001	0.015
Freq.null	0.954	0.760	0.785	0.928	0.102

315 When $K = 4$ with non-zero outcome correlations, MR-AHC tends to identify more clus-
316 ters than the ground truth. This feature can be rectified by incorporating accurate
317 outcome correlation information, see the results generated by applying the method with
318 the true correlation parameter (Table S2 in Appendix D). We show in Appendix A that
319 the outcome correlation depends on both the extent of sample overlap between the out-
320 come samples, and the phenotypic correlation between the outcome traits. Hence, high
321 outcome correlations are uncommon in practice. To achieve, for instance, a correlation
322 of $\rho = 0.7$, one would need perfect sample overlap and a phenotypic correlation of 0.7
323 between the two outcome traits. Even in this extreme scenario, implementing MR-AHC
324 while assuming a zero correlation performs reasonably well. The simulation results for
325 scenarios with three outcomes are presented in Appendix D, Table S1 and S3. Once again,
326 MR-AHC exhibits good performance, producing clustering results that closely align with
327 the ground truth and generally surpassing the performance of all other approaches.

328 **Estimating the causal effects of higher adiposity on type 2 dia-** 329 **betes and osteoarthritis**


330 We apply the MR-AHC method to investigate the causal relationship between body fat
331 percentage (BFP), as a measure of adiposity, and a pair of multimorbid conditions, T2D
332 and OA. We use a three-sample summary-data MR design with 487 SNPs associated
333 with BFP as instruments, accounting for the causal effects of the common risk factor
334 BFP on both of the conditions simultaneously. For comparison, we also perform variant
335 clustering using the mclust algorithm and the NAvMix method.

336

337 The clustering results of MR-AHC are presented in Figure 5, Panel (a). It detects 4
338 substantive clusters indicating heterogeneous causal effects. The cluster-specific estima-
339 tion results, obtained with the inverse-variance weighted (IVW) approach [5], are depicted
340 in Figure 5, Panel (b). Among the 4 clusters, Cluster 1 with 124 SNPs is the only cluster
341 associated with increasing risk for both conditions; Cluster 2 with 258 SNPs indicates an
342 increasing risk for T2D but a null effect for OA; both Cluster 3 (32 SNPs) and Cluster 4

343 (22 SNPs) are associated with a protective effect against T2D, and for OA, a causative
344 effect and a null effect, respectively. See Appendix E for detailed estimation results.

Panel (a) – (left) The scatter plot of the 487 SNPs associated with BFP; On the x-axis are the ratio estimates for T2D, and y-axis for OA. Each point represents a specific SNP. (right) the clustering results of MR-AHC.



Panel (b) – The cluster-specific IVW estimates and 95% confidence intervals in odds ratio for each cluster detected by MR-AHC.




Figure 5: MR-AHC clustering and estimation results of the 487 SNPs associated with BFP based on their ratio estimates on T2D and OA.

345 These results align with the conclusions drawn from previous research. For example, Mar-
346 tin et al. [24] examined the causal effects of higher adiposity on a variety of conditions
347 including T2D and OA. Their findings suggest that adiposity exerts heterogeneous effects
348 on the risk of T2D: in general, higher adiposity increases the risk of T2D, but there is a
349 metabolically “favourable” component of adiposity that reduces the risk of the condition.
350 For OA, all adiposity measures, including the metabolically favourable adiposity, consis-
351 tently identify an increasing risk. This suggests a non-metabolic weight-bearing effect as
352 a likely cause. Given this, it is reasonable to partition the variants into distinct clusters
353 along both outcome dimensions: on the T2D-estimate dimension, clustering occurs due
354 to the indication of opposing effects by different variants; on the OA-estimate dimension,
355 clustering is also likely to occur, as we may expect an adverse effect if the variants are
356 associated with fat located around the articulations in a load-bearing way, but no effect
357 elsewhere.

358

359 The clustering results generated with mclust and NAvMix are presented in Figure 6.
360 Both methods fail to segregate the variants along the OA-estimate dimension, as all clus-
361 ters indicate increasing effects, hence might have underestimated the number of clusters,
362 which also appears as an over-arching feature of the methods in the simulations. Even
363 for the T2D-estimate clustering, their results may be dubious: mclust assigns SNPs in
364 nonadjacent regions with largely opposing estimates into the same cluster (Cluster 2 in
365 blue); NAvMix either labels a large number of SNPs as ‘junk’ if setting a non-zero initial
366 noise proportion, or does not identify any noise at all with a zero initial proportion. More
367 importantly, for clusters generated by these two methods, variants tend to display sub-
368 stantial within-cluster heterogeneity in their ratio estimates, which can be a significant
369 concern for causal inference.




Figure 6: From left to right: the clustering results of the mclust algorithm with an initial noise proportion 5%; the clustering results of the NAvMix method with an initial noise proportion 0; the clustering results of the NAvMix method with an initial noise proportion 5%.

370 Biological insights into the variant clusters

371 To gain insights into the biological mechanisms linking obesity to the T2D-OA multi-
372 morbidity from the variant clusters detected by MR-AHC, we use an approach similar
373 to the one taken by previous works such as Grant et al. [25] and Wang et al. [31]. For
374 each of the clusters identified by MR-AHC, we first map the SNPs in the cluster to genes,
375 then perform gene set enrichment analysis with the mapped genes. Both steps are con-
376 ducted using the Functional Mapping and Annotation Platform (FUMA) [32]. SNPs are
377 mapped to genes using a three-way mapping strategy (positional, eQTL and chromatin
378 interactions mapping). The gene set enrichment analysis is to test if the mapped genes
379 are over-represented in a given pre-defined gene set which corresponds to a canonical
380 biological pathway or is associated with a phenotype reported from the GWAS catalog.
381 We refer to the latter as the gene-set Phenome-wide association analysis (PheWAS), or
382 just “PheWAS” for short. We integrate both lines of evidence from the pathway and Phe-
383 WAS analyses that can complement or validate each other, to infer the possible biological
384 mechanisms underlying each cluster. See Supplementary material S2 for a summary of

385 the enrichment analyses results.

386

387 First, it is likely that Cluster 2 (containing 258 SNPs, associated with increasing risk
388 of T2D) is highly pleiotropic. Based on the PheWAS analysis, this cluster is enriched
389 with a large number of phenotypes, double that for Cluster 1 which has the second most
390 (112 versus 56). These phenotypes fall into a wide range of categories, displaying no clear
391 pattern. The majority of the canonical pathways enriched for this cluster are related to
392 intermediate filament, which might not have a strong direct link with the causal relation-
393 ship under examination.

394

395 Cluster 1 (containing 124 SNPs, indicating increasing risks of both conditions) holds
396 particular significance as it aligns with our primary objective of exploring the multimor-
397 bidity of T2D and OA through obesity. The majority of the canonical pathways uniquely
398 enriched for Cluster 1 can be classified into two categories of cellular processes that are
399 closely interconnected: gene expression transcription and cellular responses to stimuli. A
400 significant example in the first category is DNA methylation, while in the second cate-
401 gory, one of the most significantly enriched pathways is associated with oxidative stress.
402 For some of the pathways, we can delve deeper into the investigation using readily avail-
403 able GWAS data. As an example, we further inspect the possible unifying pathway from
404 obesity to the T2D-OA multimorbidity via oxidative stress.

405

406 Oxidative stress (OS) is the imbalance between the production of reactive oxygen species
407 and the counteracting antioxidant defenses in the direction that favors the former, which
408 may lead to tissue injury [33]. Clinical research has established that obesity can induce
409 systemic OS through various metabolic pathways [34, 35]. Moreover, OS is evidenced
410 to exert direct effects on the development of T2D via mechanisms such as decreasing
411 insulin secretion from pancreatic β cells [36, 37]. It also plays a role in the progression
412 of OA by promoting cartilage degradation [38]. Herein, we examine the role of OS by
413 performing cluster-specific MR: we first analyze how BFP predicted by SNPs in cluster

414 1 is associated with a variety of OS biomarkers. Then for comparison, we conduct the
415 same analysis on Cluster 4, serving as a counterpart to Cluster 1 due to its relatively
416 benign nature for both conditions, manifesting a protective effect against T2D and a null
417 effect on OA.

418

419 We select 11 OS biomarkers from diverse categories. First, as endogenous antioxidants
420 are highly responsive to OS [39], we use 4 enzyme antioxidants (GST, CAT, SOD, GPX)
421 as OS injury biomarkers, which have been utilized in previous MR studies [40, 41]. One of
422 the mechanisms through which obesity induces systemic OS is chronic inflammation [34,
423 35]. We thus incorporate three traits known to mediate the pathway from inflammation
424 to OS (CRP, IL-6, TNF- α) [35] as another set of OS biomarkers. Biochemical research
425 has shown that the production of some cytokines, including IL-1 β , IL-12 and IL-8, are
426 enhanced under elevated OS levels [42, 43]. Therefore, we also include these three cy-
427 tokines in the analysis. Finally, we incorporate GDF-15, which is a biomarker for both
428 inflammation and OS [44]. See the method section for the full form of the abbreviations
429 of the biomarkers.

430

431 We estimate the effect of BFP on each of the biomarkers by two-sample MR using SNPs
432 in Cluster 1 and Cluster 4 as instruments separately. The estimates and standard errors
433 are calculated by the IVW approach. Sensitivity checks by MR-PRESSO [45] and the ro-
434 bust adjusted profile score (MR-RAPS) method [13] can be found in Appendix E. Results
435 in Z-scores are presented in Figure 7. For 8 out of 11 of these OS markers, Cluster 1 is
436 associated with increasing effects, while Cluster 4 is associated with declining effects. For
437 CAT and CRP, Cluster 1 and Cluster 4 have effects in the same direction, but Cluster 1
438 is either associated with a larger increasing effect (CRP), or a smaller decreasing effect
439 (CAT). The only exception is SOD, on which the increasing effect of Cluster 1 is smaller
440 than that of Cluster 4.

441

442 Overall, we can see a clear heterogeneity pattern between Cluster 1 and Cluster 4 in

443 their cluster-specific effects on the OS biomarkers, which supports that Cluster 1 is asso-
 444 ciated with an elevated level of oxidative stress, while it may be the opposite for Cluster
 445 4. These results align with the existing findings regarding adiposity and oxidative stress:
 446 higher adiposity is in general associated with elevated oxidative stress, but fat patterns
 447 featured with a smaller waist-to-hip ratio (WHR) may be related to less oxidative damage
 448 [35, 46]. This correlation between WHR and OS is observed in Cluster 4, as we will show
 449 later that this cluster is associated with a decreasing WHR.

450




Figure 7: Results of the two-sample MR estimating the effects of BFP on the 11 oxidative stress biomarkers and 2 psychological disorders using variants in Cluster 1 and Cluster 4 as instruments respectively. Estimates are given by the IVW approach, presented in the form of Z-scores (the ratio of the estimate and the standard error). "*" represents significance at the p-value 0.05; "***" for the first 11 traits represents significance at 0.05/11, for the last two traits at 0.05/2.

451 Complementary evidence that may be related to the shared pathway via oxidative stress
 452 can be found in the PheWAS results for Cluster 1. A notable PheWAS pattern associated
 453 with this cluster is that it is enriched with quite a few psychological disorders. Clinical
 454 research has shown that OS is implicated in the development of such disorders, including
 455 bipolar disorder and depression [47], which are both significantly enriched for Cluster 1.
 456 We estimate the effects of BFP predicted by variants in respectively Cluster 1 and Cluster
 457 4 on bipolar and major depressive disorder (MDD) using two-sample MR. Results are
 458 presented in the last two columns in Figure 7. Cluster 1 is associated with increasing
 459 risks of both conditions with a significant effect on bipolar. The effects of Cluster 4, on
 460 the other hand, are both insignificant and smaller than those of Cluster 1. These results
 461 may suggest a possible direction for exploring the multimorbidity between obesity-related
 462 metabolic conditions and psychological disorders.

463

464 It is important to note that there is very likely to be intricate interactions between the
465 pathways involved in the underlying mechanism from obesity to the T2D-OA multimor-
466 bidity. For example, another canonical pathway uniquely enriched for Cluster 1 is related
467 to programmed cell death, or apoptosis. It has been well-documented that excess OS
468 plays a role in the activation of apoptosis [48], and pancreatic β -cell and chondrocyte loss
469 due to apoptosis are implicated in the development of T2D and OA respectively [49, 50].
470 Furthermore, quite a few gene expression transcription pathways enriched for Cluster 1
471 are related to epigenetic processes. Emerging evidence supports the involvement of OS
472 in epigenetic regulation of gene expression such as inducing DNA methylation changes
473 [51, 52]. Thus, additional research is warranted to further unravel the exact causal roles
474 of these pathways.

475

476 Both Cluster 3 and Cluster 4 exhibit a protective effect against T2D. The most notewor-
477 thy PheWAS pattern for these two clusters is that they are both enriched with phenotypes
478 related to fat distribution. This is particularly pronounced for Cluster 4, with 17 out of
479 42 enriched phenotypes associated with fat patterns including the WHR-related traits.
480 Also, Cluster 4 has a clear pattern regarding its enriched biological pathways: 13 out
481 of 16 of the pathways are related to ion channel activities. Ion channels are membrane
482 proteins acting as gated pathways for the passage of ions across the cell membranes [53].

483

484 To integrate the evidence from the WHR-enriched PheWAS pattern and the ion-channel-
485 enriched pathway pattern into a potential explanation of the protective mechanism against
486 T2D, one possible link may be that Cluster 4 is also enriched with several HDL-C related
487 phenotypes. Existing studies have found a negative relationship between WHR and HDL-
488 C [54, 55], i.e. smaller WHR may be associated with higher levels of HDL-C. Moreover,
489 the connection between HDL-C levels, ion channel activities, and T2D development might
490 be explained by the primary role of HDL-C in cholesterol clearance [56]. On one hand,
491 ion channels, such as the β -cell voltage-gated calcium channels, are crucial for insulin

492 secretion [57]. On the other hand, the activity of such channels can be suppressed by
493 excess membrane cholesterol [29]. Thus, the depletion of cholesterol facilitated by HDL-C
494 might positively impact the activity of the ion channels related to insulin secretion. This
495 link is evidenced by previous experimental research on mice, which shows that reduced
496 HDL-C levels are correlated with impaired glucose-induced insulin secretion [58]. This
497 is because the increased rigidity of the β -cell membrane due to cholesterol-enrichment
498 reduces the stimulation of ion channels essential for secreting insulin [59, 60].

499

500 To examine the possible protective mechanism against T2D stated above, we conduct
501 two-sample MR to examine the effects indicated by Cluster 4 on WHR (adjusted for
502 BMI), HDL-C and total cholesterol levels. The results, shown in Figure 8, are in line
503 with the hypothesized mechanism: this cluster is associated smaller WHRs, higher levels
504 of HDL-C, lower levels of total cholesterol, and consequently decreasing risk of coronary
505 artery disease (CAD).




Figure 8: Two-sample MR results estimating the effects of cluster 4-predicted BFP on the waist-to-hip ratio adjusted for BMI, HDL-C, total cholesterol and coronary artery disease. Estimates are given by the IVW approach, presented in the form of the 95% confidence intervals.

506 Discussion

507 In this paper we adapt the general method of agglomerative hierarchical clustering to the
508 summary-data Mendelian randomization setup. MR-AHC is a useful tool for interrogat-
509 ing a set of genetic variants to see if they collectively identify a single causal effect, or
510 if it is more plausible that a number of subgroups identify distinct effects driven by dif-
511 ferent biological mechanisms. The method is of particular interest when the potentially

512 heterogeneous physiological components of the exposure are not known beforehand, or
513 are difficult/expensive to measure. Of special interest is its utility as a multi-dimensional
514 clustering method in the multi-outcome MR setting, where we can elucidate the shared
515 causal pathways that underlie the co-occurrence of a range of conditions through a com-
516 mon risk factor.

517

518 In an effort to investigate the intricate mechanisms underpinning disease causation, a
519 number of approaches has been utilized to categorize genetic variants associated with
520 a specific phenotype, based on their GWAS associations with a range of traits linked
521 to that target phenotype, such as the Bayesian nonnegative matrix factorization clus-
522 tering method [61] and the NAvMix method [25]. MR-AHC is motivated similarly by
523 the purpose of exploring the diverse disease-causing pathways reflected by distinct vari-
524 ant clusters. However, it is distinctly tailored to a different scenario and employs a
525 different clustering strategy. Its primary application is rooted in the domain of causal
526 inference, specifically within the framework of MR. It groups genetic variants based on
527 their causal estimates, which integrates both their associations with the target pheno-
528 type (in this context, a common exposure) and their associations with the related traits
529 (herein, downstream outcomes). By the comparison with NAvMix through Monte Carlo
530 simulations and the real-world application, we have shown that MR-AHC has certain
531 advantages over the association-based approaches in MR settings, namely an enhanced
532 capacity to identify the patterns of the genetic variants that may mirror distinct causal
533 mechanisms between specific traits. Furthermore, while the variant clusters discovered
534 through association-based methods may have broad biological implications encompassing
535 a wide range of traits, those detected by MR-AHC are precisely focused on elucidating a
536 specific causal relationship. Consequently, pathway information derived from each cluster
537 identified by MR-AHC offers a higher degree of relevance and specificity for the causal
538 relationship under examination.

539

540 MR-AHC possesses the features that it does not require pre-specifying the number of

541 clusters, and that alongside detecting meaningful clusters it can also identify and label
542 null and junk clusters without an initial specification on the proportion of ‘noise’. While
543 for hierarchical clustering algorithms, it can be difficult to choose the ‘optimal’ dissimilar-
544 ity metric, linkage and number of clusters on the dendrogram to yield reliable clustering
545 results, studies in the field of model selection [17, 62] provide the theoretical basis for
546 MR-AHC to ensure highly accurate results. We have adapted the original AHC method
547 in Apfel and Liang [17] to accommodate the varying degrees of uncertainty exhibited in
548 summary-data estimates due to allele frequency differences across SNPs. Moreover, our
549 method is capable of handling outliers in the variant-specific estimates with our outlier
550 removal procedure. It should be noted that all the aforementioned methods assign vari-
551 ants to clusters in a probabilistic (i.e. ‘soft’) way, while MR-AHC do the clustering in
552 a deterministic (i.e. ‘hard’) manner. Although we view this as a strength, some may
553 view its lack of stochasticity as a disadvantage. For this reason we plan to develop a
554 framework to quantify the sensitivity of MR-AHC clustering results to small changes in
555 the data and thresholding rule used.

556

557 We showed in simulations that, in situations of sample overlap in the outcome data,
558 incorporating the correct correlation information can improve the performance of the
559 method. Nevertheless, it is in general not a significant concern if the correlation esti-
560 mates are set to zero. Our method is currently focused on the problem of estimating a
561 causal relationship between the shared exposure and the downstream outcomes without
562 accounting for the direct causality between the outcomes. In our application example,
563 various existing evidence supports the absence of direct causality between T2D and OA
564 [63, 64]. However, we show in Appendix C that even if direct causality exists, our method
565 is still applicable, as the clustering of the variants associated with the common exposure
566 are generally robust to the outcome causality. The challenge then shifts to estimating
567 the direct causal effect of the exposure on a particular outcome while considering other
568 outcome traits as an additional risk factor, or accepting that the original estimates repre-
569 sent total causal effects via the outcome in question. Given this, another potential future

570 extension of our work is to extend the method to the multi-exposure framework, with the
571 additional flexibility to consider genetic sub-structure within each exposure.

572 Materials and Methods

573 Model setup

574 We start from the individual-level model underlying the variant-exposure and variant-
575 outcome summary associations. We assume a general linear IV model for the MR frame-
576 work allowing for multiple outcomes with a shared exposure, which accounts for pleiotropy
577 and heterogeneous causal mechanisms. We also assume that the causal effects from the
578 exposure to the outcomes via different pathways are additive. Therefore, without loss
579 of generality, we model the causality heterogeneity using additive sub-components of the
580 exposure. Let the common exposure X be denoted by $X = X_1 + \dots + X_k$ where X_k
581 is the k -th sub-component in X and $k = 1, \dots, K$. Let the p -th observed outcome be
582 denoted by the scalar Y_p where $p = 1, \dots, P$ and $P \geq 2$ in a multi-outcome MR. The
583 vector $\mathbf{G} = (G_1, \dots, G_J)'$ is used to denote the J genetic variants used as instruments.
584 We then have the following linear structural model:

$$U = \sum_{j=1}^J \eta_j G_j + \epsilon_U, \quad (1)$$

$$X_k = \sum_{j=1}^J \delta_{kj} G_j + q_{xk} U + \epsilon_{Xk}, \quad (2)$$

$$X = \sum_{k=1}^K X_k, \quad (3)$$

$$Y_p = \sum_{k=1}^K \theta_{kp} X_k + \sum_{j=1}^J \psi_{jp} G_j + q_{yp} U + \epsilon_{Yp}, \quad (4)$$

585 where

- 586 • U represents the uncontrolled confounding between Y_p and any sub-component of
587 X , with the strength of confounding determined by parameters q_{xk} and q_{yp} ;

588 • ϵ_U , ϵ_{X_k} and ϵ_{Y_p} are error terms affecting U , X_k and Y respectively, and we assume
589 $E(\epsilon_U G_j) = E(\epsilon_{X_k} G_j) = 0$ for all $j = 1, \dots, J$;

590 • $\theta_{1p}, \dots, \theta_{Kp}$ represent the heterogeneous causal effects of X on Y_p .

591 We maintain the assumption that all the variants are independent with each other, and
592 therefore inspect the relationship between each individual variant G_j and X as well as
593 between G_j and Y_p . First, from (1) and (2), we obtain the reduced-form relationship
594 between X_k and G_j as

$$X_k = \gamma_{kj} G_j + \xi_{Xkj},$$

595 where the total effect of G_j on X_k is $\gamma_{kj} = \delta_{kj} + q_{xk}\eta_j$. The error term ξ_{Xkj} is defined
596 implicitly, but from the the previous assumptions $E(\epsilon_U G_j) = E(\epsilon_{X_k} G_j) = 0$ and that G_j
597 is independent with all other variants, we have $E(\xi_{Xkj} G_j) = 0$ as well. It follows from
598 (3) that the overall relationship between G_j and the exposure X is

$$X = \gamma_j G_j + \xi_{Xj} \tag{5}$$

599 where

$$\gamma_j = \sum_{k=1}^K \gamma_{kj} = \sum_{k=1}^K \delta_{kj} + \eta_j \sum_{k=1}^K q_{xk}, \tag{6}$$

600 and the error term $\xi_{Xj} = \sum_{k=1}^K \xi_{Xkj}$ with $E(\xi_{Xj} G_j) = 0$. We assume that the relevance
601 condition for the instruments is satisfied at the scale of the overall exposure X so that
602 $\gamma_j \neq 0$ for $j = 1, \dots, J$.

603

604 Now we inspect the reduced-relationship between G_j and Y_p . It follows from (4) that
605 the pleiotropic effect of G_j on Y_p can be derived as $\alpha_{jp} = \psi_{jp} + q_{yp}\eta_j$. Additionally by
606 plugging (1) and (2) into (4), the overall reduced-form between Y_p and G_j is

$$Y_p = \Gamma_{jp} G_j + \xi_{Ypj}, \tag{7}$$

607 where

$$\Gamma_{jp} = \sum_{k=1}^K \theta_{kp} \gamma_{kj} + \alpha_{jp} = \sum_{k=1}^K \theta_{kp} \delta_{kj} + \eta_j \left(\sum_{k=1}^K \theta_{kp} q_{xk} + q_{yp} \right) + \psi_{jp}. \quad (8)$$

608 The correlation between the implicitly-defined error term ξ_{Ypj} and G_j depends on the
609 correlation between ϵ_{Yp} from Equation 4 and G_j . If $E(\epsilon_{Yp} G_j) = 0$, then ξ_{Ypj} and G_j
610 are also uncorrelated. In this case, for the G_j - Y_p association estimate (denoted by $\hat{\Gamma}_{jp}$)
611 generated from a GWAS by regressing Y_p on G_j in a given sample, we have

$$\hat{\Gamma}_{jp} \xrightarrow{p} \Gamma_{jp}$$

612 as the sample size $n \rightarrow \infty$. Similarly, for the G_j - X association estimated in a GWAS
613 (denoted by $\hat{\gamma}_j$) in a sample independent from the G_j - Y_p sample, we have

$$\hat{\gamma}_j \xrightarrow{p} \gamma_j$$

614 as $n \rightarrow \infty$. Then for the variant-specific causal estimate of G_j , defined as $\hat{\beta}_{jp} = \hat{\Gamma}_{jp} / \hat{\gamma}_j$,
615 we have

$$\hat{\beta}_{jp} \xrightarrow{p} \beta_{jp} \quad \text{and} \quad \beta_{jp} = \frac{\Gamma_{jp}}{\gamma_j} = \frac{\sum_{k=1}^K \theta_{kp} \gamma_{kj} + \alpha_{jp}}{\sum_{k=1}^K \gamma_{kj}}.$$

616 In words, as the sample size n goes to infinity, each $\hat{\beta}_{jp}$ converges to their variant-specific
617 causal estimand β_{jp} , which is the causal effect from X to Y_p identified using G_j as in-
618 strument. In the simple case where G_j only instruments one sub-component X_k , the
619 variant-specific causal estimand then becomes:

$$\beta_{jp} = \frac{\theta_{kp} \gamma_{kj} + \alpha_{jp}}{\gamma_{kj}} = \theta_{kp} + \frac{\alpha_{jp}}{\gamma_{kj}}. \quad (9)$$

620 Equation 9 reflects the possible sources of mechanistic heterogeneity among the variant-
621 specific estimates: heterogeneous causal effect from the exposure to the outcome, and
622 pleiotropic effects. We aim to group the genetic variants into distinct clusters such that
623 within each cluster, all variants identify the same causal effect. More generally, for the

624 multi-outcome MR with $P \geq 2$ outcomes, with a given variant G_j , we combine all $\hat{\beta}_{jp}$
 625 and β_{jp} for $p = 1, \dots, P$ into the vectors $\hat{\beta}_j = (\hat{\beta}_{j1}, \dots, \hat{\beta}_{jP})'$ and $\beta_j = (\beta_{j1}, \dots, \beta_{jP})'$
 626 respectively. We propose the MR-AHC method, elaborated in the subsequent section,
 627 to divide the genetic variants into distinct clusters based on the similarity of their ratio
 628 estimates $\hat{\beta}_j$, so that variants with the same estimand β_j are in the same cluster.

629

630 Thus far, we have inspected the case where there is no residual correlation between
 631 G_j and ϵ_{Yp} in Equation 4, i.e. $E(\epsilon_{Yp}G_j) = 0$. In a multi-outcome MR model, this rela-
 632 tionship can be violated if there is direct causality between the outcome variables. For
 633 example, consider two outcomes Y_p and Y_q , if Y_q causally affects Y_p directly, then it will
 634 enter Equation 4 as part of ϵ_{Yp} , hence the error term may be correlated with G_j . We
 635 show in Appendix C that the clustering results of the variants are in general not affected
 636 by the additional direct causality between the outcomes, but the causal effects identified
 637 by each cluster are the total effects including the outcomes causality, instead of the direct
 638 effects from the exposure to the outcomes. In this paper, we mainly focus on the case
 639 without the direct outcome causality.

640 The MR-AHC algorithm

641 We make the following normality assumption on the summary statistics described in
 642 the previous section: $\sqrt{n} \left(\begin{pmatrix} \hat{\Gamma}_{jp} \\ \hat{\gamma}_j \end{pmatrix} - \begin{pmatrix} \Gamma_{jp} \\ \gamma_j \end{pmatrix} \right) \xrightarrow{d} N \left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, \begin{pmatrix} \sigma_{Yjp}^2 & 0 \\ 0 & \sigma_{Xj}^2 \end{pmatrix} \right)$, for
 643 $j = 1, \dots, J$ and $p = 1, \dots, P$. It follows that $\sqrt{n} (\hat{\beta}_{jp} - \beta_{jp}) \xrightarrow{d} N(0, \sigma_{jp}^2)$. The estimates
 644 of the standard errors of $\hat{\gamma}_j$ and $\hat{\Gamma}_{jp}$, denoted by $se(\hat{\gamma}_j)$ and $se(\hat{\Gamma}_{jp})$, are generally given
 645 by the corresponding GWAS, hence taken as known. The standard error of $\hat{\beta}_{jp} = \hat{\Gamma}_{jp}/\hat{\gamma}_j$
 646 can then be obtained using the Delta method as $\hat{v}_{jp} = \sqrt{\frac{se(\hat{\Gamma}_{jp})^2 + \hat{\beta}_{jp}^2 se(\hat{\gamma}_j)^2}{\hat{\gamma}_j^2}}$. But it is
 647 typically approximated by $\hat{v}_{jp} = se(\hat{\Gamma}_{jp})/|\hat{\gamma}_j|$ since $se(\hat{\gamma}_j)$ is deemed negligible when
 648 we only use variants that pass a genome-wide significance threshold as instruments [11].
 649 When there are multiple outcomes, let $\hat{\Sigma}_j$ be the estimate of the covariance matrix of
 650 $\hat{\beta}_j$. The diagonal entries of $\hat{\Sigma}_j$ are just the variances of $(\hat{\beta}_{j1}, \dots, \hat{\beta}_{jP})'$, i.e. $(\hat{v}_{j1}^2, \dots, \hat{v}_{jP}^2)'$.

651 The off-diagonal entries of $\widehat{\Sigma}_j$ are the pairwise covariances of $(\widehat{\beta}_{j1}, \dots, \widehat{\beta}_{jP})'$. We show
 652 in Appendix A that the covariances are zero if the outcome samples are non-overlapping
 653 and/or the phenotypic correlations between the outcome traits are zero, otherwise, they
 654 can be estimated using LD score regression [28].

655

656 With the summary statistics $\{\widehat{\beta}_j, \widehat{\Sigma}_j\}_{j=1}^J$ as inputs, we apply MR-AHC to discover the
 657 variant clusters using a two-step procedure: Step 1 (agglomerative hierarchical cluster-
 658 ing) generates a decision path from $\mathcal{K} = J$ to $\mathcal{K} = 1$ clusters; Step 2 (downward testing)
 659 re-traces the path from $\mathcal{K} = 1$ to $\mathcal{K} = J$ until the optimal cluster choice \mathcal{K}_{opt} is chosen.

660 The first step is summarized as follows:

661 **Step 1. Ward's algorithm [65]**

662 1. **Initialization:** Each variant-specific estimate is viewed as a cluster on its own.

663 Hence, initially, the total number of clusters is $\mathcal{K} = J$.

664 2. **Merging:** The two clusters that are closest as measured by their weighted squared

665 Euclidean distance are merged into a new cluster. Without loss of generality, as-

666 sume this is satisfied by cluster \mathcal{S}_k and \mathcal{S}_l . $\widehat{\beta}_{\mathcal{S}_k}^{IVW}$ is defined as the inverse-variance

667 weighted mean of all the variant-specific estimates in \mathcal{S}_k , as follows:

$$\widehat{\beta}_{\mathcal{S}_k}^{IVW} = (\widehat{\beta}_{\mathcal{S}_k,1}^{IVW}, \dots, \widehat{\beta}_{\mathcal{S}_k,P}^{IVW})'$$

668 where

$$\widehat{\beta}_{\mathcal{S}_k,p}^{IVW} = \frac{\sum_{j \in \mathcal{S}_k} \widehat{\beta}_{jp} w_{jp}}{\sum_{j \in \mathcal{S}_k} w_{jp}} \quad (10)$$

669 with $w_{jp} = 1/v_{jp}^2$ for $p = 1, \dots, P$. $\widehat{\beta}_{\mathcal{S}_l}^{IVW}$ for Cluster \mathcal{S}_l can be defined similarly.

670 Then the weighted squared Euclidean distance between \mathcal{S}_k and \mathcal{S}_l is defined as

$$\mathcal{D}_{k,l} = (\widehat{\beta}_{\mathcal{S}_k}^{IVW} - \widehat{\beta}_{\mathcal{S}_l}^{IVW})' \widehat{\Omega}_{k,l}^{-1} (\widehat{\beta}_{\mathcal{S}_k}^{IVW} - \widehat{\beta}_{\mathcal{S}_l}^{IVW}). \quad (11)$$

671 The $P \times P$ matrix $\widehat{\Omega}_{k,l}$ is defined as follows: let $W_{kp} = \sum_{j \in \mathcal{S}_k} w_{jp}$, and $W_{lp} =$

672 $\sum_{j \in \mathcal{S}_l} w_{jp}$ for $p = 1, \dots, P$. Consider the entry at the i -th column and the r -th row

673 of $\widehat{\Omega}_{k,l}$ with $i, r \in \{1, \dots, P\}$, denoted by cov_{ir} . We have

$$cov_{ir} = \frac{\rho_{ir}}{W_{ki}W_{kr}} \sum_{j \in \mathcal{S}_k} \frac{\widehat{\gamma}_j^2}{se(\widehat{\Gamma}_{ji})se(\widehat{\Gamma}_{jr})} + \frac{\rho_{ir}}{W_{li}W_{lr}} \sum_{j \in \mathcal{S}_l} \frac{\widehat{\gamma}_j^2}{se(\widehat{\Gamma}_{ji})se(\widehat{\Gamma}_{jr})},$$

674 where ρ_{ir} is the correlation between $\widehat{\Gamma}_{ji}$ and $\widehat{\Gamma}_{jr}$, which is assumed to be constant
675 across $j = 1, \dots, J$. See Appendix A for details.

676 **3. Iteration:** The merging step is repeated until all the variant-specific estimates are
677 in one cluster of size J .

678 After generating the clustering path using Step 1, we are left with a $\mathcal{K} = 1$ super-cluster
679 containing all variants. We then re-trace the pathway to select the optimal value of \mathcal{K}
680 using a downward testing procedure originally proposed by Andrews [62], operating as
681 follows:

682 **Step 2.** Downward testing procedure.

683
684 Firstly, define Q_{fg} to be the Cochran's Q statistic [27] associated with the g -th cluster at
685 level f of the clustering path, denoted by \mathcal{S}_{fg} . Also define T_{fg} to be the $(1 - \zeta)$ significance
686 threshold of a χ^2 distribution on $P \times (|\mathcal{S}_{fg}| - 1)$ degrees of freedom with $\zeta = 0.1/\log(n)$,
687 n is the sample size, and $|\mathcal{S}_{fg}|$ is the number of variants in \mathcal{S}_{fg} . Q_{fg} is defined as follows:
688 for the p -th outcome, let $\widehat{\beta}^p$ be the vector of length $|\mathcal{S}_{fg}|$ with the j -th entry being $\widehat{\beta}_{jp}$
689 where $j \in \mathcal{S}_{fg}$. Combine all $\widehat{\beta}^p$ into a vector of length $P \times |\mathcal{S}_{fg}|$ for all $p = 1, \dots, P$,
690 denoted by \mathcal{B}_{fg} . Let $\widehat{\beta}_{IVW}^p$ be the IVW mean of all the estimates in $\widehat{\beta}^p$ as defined in (10),
691 and $\mathbf{1}$ be a vector of 1 of length $|\mathcal{S}_{fg}|$. Then combine all the $|\mathcal{S}_{fg}|$ -length vector $\mathbf{1}\widehat{\beta}_{IVW}^p$
692 into a vector of length $P \times |\mathcal{S}_{fg}|$ for all $p = 1, \dots, P$, denoted by \mathcal{B}_{fg}^{IVW} . Then Q_{fg} is

$$Q_{fg} = (\mathcal{B}_{fg} - \mathcal{B}_{fg}^{IVW})' \widehat{\Phi}_{fg}^{-1} (\mathcal{B}_{fg} - \mathcal{B}_{fg}^{IVW}), \quad (12)$$

693 where $\widehat{\Phi}_{fg}$ is a matrix that can be partitioned into $P \times P$ blocks. The block on the i -th
694 column and r -th row, denoted by $\widehat{\Phi}_{ir}$, is a $|\mathcal{S}_{fg}| \times |\mathcal{S}_{fg}|$ dimension diagonal matrix. The
695 j -th diagonal entry equals to $\frac{\rho_{ir} se(\widehat{\Gamma}_{ji}) se(\widehat{\Gamma}_{jr})}{\widehat{\gamma}_j^2}$ for $j \in \mathcal{S}_{fg}$.

- 696 1. Starting from the cluster that contains all the variants, calculate the global Q statis-
697 tic, Q_{11} , on all the ratio estimates;
- 698 2. If $Q_{11} < T_{11}$, then stop and assume that all the variants form a single cluster. If
699 $Q_{11} \geq T_{11}$, then revert to the variant clusters on the next level of the path, where
700 the number of clusters is $\mathcal{K}=2$;
- 701 3. Calculate Q statistics for the two sub-clusters separately, Q_{21} and Q_{22} ;
- 702 4. If both $Q_{21} < T_{21}$ and $Q_{22} < T_{22}$, then stop. Otherwise, continue to the next level
703 where $\mathcal{K}=3$;
- 704 5. Repeat steps 3-4 until a $\mathcal{K} \in (1, \dots, J)$ is arrived at for which no sub-cluster hetero-
705 geneity statistic rejects at its given threshold.

706 In implementing the MR-AHC method, in addition to the baseline procedure summarized
707 in Step 1 and 2, we propose an extension of the method to handle outliers in the ratio
708 estimates: after we run Step 1 and 2 and obtain the clustering results, within each
709 detected cluster, calculate each individual variant's contribution to the overall Q statistic.
710 The individual Q statistic, calculated using (12) with only estimates of that variant,
711 approximately follows a χ^2_p distribution [11], and variants with large individual Q (here
712 defined as the p-value of the individual Q below 5%) are viewed as outliers. We remove
713 the outliers from each detected cluster, and re-run Step 1 and 2 with all the remaining
714 variants. All the outliers are then assigned to the junk cluster.

715 Monte Carlo simulations

716 For all the simulation designs, we simulate two/three-sample summary data based on
717 the data generating process defined in Model (1)-(4) with all sample sizes equal to $N =$
718 60,000. Here we fix $\psi_j = 0$. We assume that G_j , X and Y_p are normalized with $Var(G_j) =$
719 $Var(X) = Var(Y_p) = 1$ and $\mathbb{E}[G_j] = \mathbb{E}[X] = \mathbb{E}[Y_p] = 0$. We also assume that the
720 covariances between the variants are 0, $Cov(G_j, G_i) = 0$ for $i \neq j$. According to Equation

721 (6) and (8), the variant-exposure and variant-outcome summary statistics are generated
722 in the following way:

$$\begin{aligned}\widehat{\beta}_{X_j} &= \sum_{k=1}^K \delta_{kj} + \eta_j \sum_{k=1}^K q_{xk} + N(0, 1/N), \\ \widehat{\beta}_{Y_{jp}} &= \sum_{k=1}^K \theta_{kp} \delta_{kj} + \eta_j \left(\sum_{k=1}^K \theta_{kp} q_{xk} + q_{yp} \right) + e_{Y_{jp}},\end{aligned}$$

723 for $j = 1, \dots, J$ with $J = 100$ and $p = 1, 2$ or $p = 1, 2, 3$. The normally distributed random
724 variables $N(0, 1/N)$ add the random component to $\widehat{\beta}_{X_j}$ that mimics the asymptotically
725 normal distribution of the statistics obtained from GWAS with standardized data. The
726 random error of $\widehat{\beta}_{Y_{jp}}$, denoted by $e_{Y_{jp}}$, is generated from a multivariate normal distri-
727 bution for the multiple outcomes. All the variance terms of this multivariate normal
728 distribution are set to $1/N$. When there are $P = 2$ outcomes, the covariance equals
729 ρ/N with $\rho = 0, 0.2$, and 0.7 for the zero, low, and high outcome correlation settings
730 respectively. When there are $P = 3$ outcomes, the pair-wise outcome correlation equals
731 to $\rho_{ij} = \rho^{|i-j|}$ where $i, j \in \{1, 2, 3\}$ and $i \neq j$ with $\rho = 0, 0.2$ and 0.7 for three different
732 settings. Then the standard errors of $\widehat{\beta}_{X_j}$ and $\widehat{\beta}_{Y_{jp}}$ are given by

$$se(\widehat{\beta}_{X_j}) = se(\widehat{\beta}_{Y_{jp}}) = \sqrt{1/N}.$$

733 To simulate the summary statistics, we need to set the values of the following parameters:
734 θ_{kp} (the causal effect of the sub-component X_k on Y_p), δ_{kj} (the effect of variant G_j on X_k),
735 η_j (the effect of variant G_j on the uncontrolled confounder U), and q_{xk}, q_{yp} (the effect
736 of U on X_k and Y_p respectively). Let the variation in U explained by all the variants
737 be h_U^2 , and the variation in X_k directly explained by all the variants (not through U) be
738 h_k^2 . Then given the values of h_U^2 and h_k^2 , parameters θ_{kp}, q_{xk} and q_{yp} are set as constants
739 under the following restrictions to make $Var(X) = Var(Y_p) = 1$ feasible:

$$\sum_{k=1}^K h_k^2 + h_U^2 \sum_{k=1}^K q_{xk}^2 < 1, \quad \sum_{k=1}^K \theta_{kp}^2 h_k^2 + h_U^2 \sum_{k=1}^K q_{xk}^2 \theta_{kp}^2 + q_y^2 h_U^2 < 1.$$

740 When there are $K = 4$ substantive clusters (with 15, 15, 30, 30 variants respectively) and
741 one noise cluster (with 10 variants), let $h_U^2 = 0.05$ and $h_k^2 = (0, 0.05, 0.1, 0.1, 0.005)$ for
742 $k = 1, \dots, 5$ with the last entry for the junk cluster. Set $q_{xk} = 1$ for the first cluster, which
743 corresponds to the correlated pleiotropy pathway, and $q_{xk} = 0$ for all the other clusters.
744 When there are two outcomes, let $q_{y1} = 0.4$ and $q_{y2} = 0.1$. The causal effect param-
745 eters are set as $\theta_{k1} = (0.1, 0.3, 0.5, 0.4)$ for the first outcome, and $\theta_{k2} = (0.2, -0.3, 0.6, 0)$
746 for the second outcome, with $k = 1, \dots, 4$. Causal effects of the 10 noise variants are
747 generated from $N(0, 1)$. When there are three outcomes, additionally set $q_{y3} = 0.2$ and
748 $\theta_{k3} = (-0.2, 0.3, 0, 0.3)$.

749

750 When there is $K = 1$ substantive cluster (with 90 variants) and one noise cluster (with
751 10 variants), set $h_U^2 = q_{xk} = q_{yp} = 0$ and $h_k^2 = (0.1, 0.005)$. The causal effects of X on all
752 the outcomes are set to zero. In all simulation designs, δ_{kj} and η_j are generated from the
753 uniform distribution $U[0.1, 0.3]$, and are randomly assigned to be positive or negative,
754 then re-scaled as $\delta_{kj} \sqrt{h_k^2} / \sqrt{\sum_{j=1}^J \delta_{kj}^2}$ and $\eta_j \sqrt{h_U^2} / \sqrt{\sum_{j=1}^J \eta_j^2}$ to make sure that variations
755 in U and X_k explained by the variants equal to h_u^2 and h_k^2 respectively.

756

757 The Rand index [66] is a quantity which measures the similarity between two clustering
758 outcomes with values between 0 and 1. It is given by $R = (a + b) / \binom{p}{2}$. Here, a denotes
759 the number of pairs of objects that are classified as belonging to the same cluster in both
760 clustering outcomes and b is the number of pairs of objects that are classified in different
761 clusters by both clustering outcomes. R values close to 1 indicate good agreement and
762 values close to 0 indicate poor agreement between two clustering outcomes. Here the
763 Rand index is calculated with variants assigned to the substantive clusters by the meth-
764 ods. The mean absolute error (MAE) and mean squared error (MSE) are calculated as
765 follows:

$$MAE_p = \frac{1}{J'} \sum_{j=1}^{J'} |\beta_{jk} - \hat{\beta}_{jk}|, \quad MSE_p = \frac{1}{J'} \sum_{j=1}^{J'} (\beta_{jk} - \hat{\beta}_{jk})^2,$$

766 where J' is the number of variants that are not assigned to the junk cluster by the meth-
767 ods, and do not belong to the junk cluster by the ground truth. β_{jk} is the true causal
768 effect associated with the cluster which G_j truly belongs to, and $\hat{\beta}_{jk}$ is the causal esti-
769 mate associated with the cluster which G_j is assigned to by the methods. The subscript
770 p denotes the p -th outcome, and the overall MAE and MSE are calculated as means over
771 all the outcomes.

772

773 MR-AHC is performed with the outlier-robust variation as described previously. To avoid
774 spurious clusters, we only report the detected clusters containing more than 4 variants.
775 Small clusters with less than 4 variants are subsumed into the junk cluster. The inputs
776 for NAvMix are standardized before being supplied to the algorithm, as recommended
777 in Grant et al. [25]. The cluster-specific causal estimates are obtained using the IWV
778 approach. One exception is that if there is overdispersion within a detected cluster, as
779 indicated by a non-zero I^2 , then the cluster-specific estimate and its standard error are
780 calculated using MR-RAPS [13] to account for the within-cluster overdispersion.

781 **Clustering analysis on the BFP associated genetic variants based** 782 **on the causal estimates of T2D and OA**

783 We use SNP-BFP summary data from a GWAS study based on UK Biobank individuals
784 from Martin et al. [24], including 696 SNPs at genome-wide significance ($p < 5 \times 10^{-8}$).
785 The T2D GWAS statistics are from Mahajan et al. [67], which combine 31 published
786 GWAS studies but exclude the UK Biobank individuals. The SNP-OA summary statis-
787 tics are from a FinnGen GWAS (code: M13_ARTHROSIS_INCLAVO) [68]. Only SNPs
788 present in all three datasets are used for analyses (487 in total). SNPs are orientated
789 across all three datasets in the direction of increasing the exposure. The T2D and OA

790 samples are non-overlapping, therefore for each SNP, the covariance between the SNP-
791 T2D estimate and SNP-OA estimate is treated as zero.

792

793 In implementing the MR-AHC method, we use the effective sample size [30] of the T2D
794 GWAS sample ($n = 193,440$) to calculate the threshold p-value $0.1/\log(n)$ in the binary
795 outcome setting for Cochran's Q test and the post-selection Wald test in detecting the
796 null clusters. Clustering results of MR-AHC are obtained using an iterated outlier re-
797 moval procedure: this performs the outlier removal and re-fitting indefinitely until the
798 individual p-values of the Q statistics for all SNPs are above 5%. The cluster-specific
799 causal estimates and standard errors are calculated with the IVW approach. For clusters
800 with overdispersion indicated by a non-zero I^2 , the estimates are obtained using MR-
801 RAPS to account for the within-cluster overdispersion. We set the initial proportion of
802 noise SNPs as 5% for both mclust and NAvMix.

803 **Post-clustering analysis**

804 We map SNPs in each cluster to genes using the SNP2GENE function in FUMA based
805 on positional mapping (with deleterious coding SNPs) [69], eQTL mapping, and chro-
806 matin interaction mapping. This three-way mapping strategy is used in the applied
807 examples in the original paper introducing FUMA [32]. The uploaded SNPs are also
808 set to be the pre-defined lead SNPs. All default settings are applied, with the excep-
809 tion that we set the reference panel population as "UKB release2b 10k European". For
810 eQTL mapping, following the practice in Grant et al. [25], we select tissue types from the
811 following data sources: eQTL catalogue, PsychENCODE, van der Wijst et al. scRNA
812 eQTLs, DICE, eQTLGen, Blood eQTLs, MuTHER, xQTLServer, ComminMind Consor-
813 tium, BRAINEAC and GTEx v8 [70–79]. For chromatin interaction mapping, we select
814 all available Hi-C datasets. The gene-set enrichment analysis is conducted using the
815 GENE2FUNC function in FUMA. For the mapped genes corresponding to each cluster,
816 we perform the hypergeometric test to check if the mapped genes are over-represented
817 in a pre-defined gene set. Multi-testing correction with the Benjamini-Hochberg proce-

818 dure is applied, with the adjusted p-value ≤ 0.05 as threshold [32]. The pre-defined gene
819 sets for canonical pathways and gene ontology processes are obtained from MsigDB and
820 WikiPathways [80, 81]. Gene sets for phenotypes are from GWAS catalog [82].

821

822 To test how the variant clusters are associated with oxidative stress, we create a list
823 of 11 OS biomarkers from various categories, including: glutathione transferase (GST),
824 catalase(CAT), superoxide dismutase(SOD), glutathione peroxidase (GPX), C-reactive
825 protein (CRP), Interleukin 6 (IL-6), Tumor necrosis factor alpha (TNF- α), Interleukin
826 1 beta (IL-1 β), Interleukin 12 (IL-12), Interleukin 8 (IL-8) and Growth/differentiation
827 factor-15 (GDF-15). The GWAS summary statistics for the four antioxidants (GST, CAT,
828 SOD, GPX) and CRP are obtained from the GWAS of Sun et al. [83]; for GDF-15, the
829 GWAS of Gudjonsson et al. [84]; for the rest five cytokines, the GWAS of Ahola-Olli et al.
830 [85] and Kalaoja et al. [86]. Summary statistics for bipolar disorder and major depres-
831 sion disorder are taken from two GWAS studies conducted by the Psychiatric Genomics
832 Consortium [87, 88]. For MR analyses associated with Cluster 4, the WHR (adjust for
833 BMI) statistics are obtained from a GWAS conducted by the GIANT Consortium [89];
834 for the HDL-C and total cholesterol data, the GWAS from the Global Lipids Genetics
835 Consortium [90]; for CAD, the GWAS from the CARDIoGRAMplusC4D Consortium
836 [91].

837 References

- 838 [1] George Davey Smith and Shah Ebrahim. “Mendelian randomization: prospects,
839 potentials, and limitations”. In: *International journal of epidemiology* 33.1 (2004),
840 pp. 30–42.
- 841 [2] Debbie A Lawlor et al. “Mendelian randomization: using genes as instruments for
842 making causal inferences in epidemiology”. In: *Statistics in medicine* 27.8 (2008),
843 pp. 1133–1163.
- 844 [3] Vanessa Didelez and Nuala Sheehan. “Mendelian randomization as an instrumental
845 variable approach to causal inference”. In: *Statistical methods in medical research*
846 16.4 (2007), pp. 309–330.
- 847 [4] Tom M Palmer et al. “Using multiple genetic variants as instrumental variables
848 for modifiable risk factors”. In: *Statistical methods in medical research* 21.3 (2012),
849 pp. 223–242.

- 850 [5] Jack Bowden and Michael V. Holmes. “Meta-analysis and Mendelian randomiza-
851 tion: A review”. In: *Research Synthesis Methods* 10.4 (2019), pp. 486–496. DOI:
852 <https://doi.org/10.1002/jrsm.1346>. URL: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jrsm.1346>.
853
- 854 [6] Patrick MA Sleiman and Struan FA Grant. “Mendelian randomization in the era of
855 genomewide association studies”. In: *Clinical chemistry* 56.5 (2010), pp. 723–728.
- 856 [7] Miguel A Hernán and James M Robins. “Instruments for causal inference: an epi-
857 demologist’s dream?” In: *Epidemiology* (2006), pp. 360–372.
- 858 [8] Fabiola Del Greco M et al. “Detecting pleiotropy in Mendelian randomisation stud-
859 ies with summary data and a continuous outcome”. In: *Statistics in medicine* 34.21
860 (2015), pp. 2926–2940.
- 861 [9] Stephen Burgess et al. “Guidelines for performing Mendelian randomization inves-
862 tigations: update for summer 2023”. In: *Wellcome open research* 4 (2019).
- 863 [10] Gibran Hemani, Jack Bowden, and George Davey Smith. “Evaluating the potential
864 role of pleiotropy in Mendelian randomization studies”. In: *Human Molecular Ge-
865 netics* 27.R2 (May 2018), R195–R208. ISSN: 0964-6906. DOI: 10.1093/hmg/ddy163.
866 URL: <https://doi.org/10.1093/hmg/ddy163>.
- 867 [11] Jack Bowden et al. “Improving the accuracy of two-sample summary-data Mendelian
868 randomization: moving beyond the NOME assumption”. In: *International Journal
869 of Epidemiology* 48.3 (Dec. 2018), pp. 728–742. ISSN: 0300-5771. DOI: 10.1093/
870 *ije/dyy258*. URL: <https://doi.org/10.1093/ije/dyy258>.
- 871 [12] Jack Bowden et al. “A framework for the investigation of pleiotropy in two-sample
872 summary data Mendelian randomization”. In: *Statistics in medicine* 36.11 (2017),
873 pp. 1783–1802.
- 874 [13] Qingyuan Zhao et al. “Statistical inference in two-sample summary-data Mendelian
875 randomization using robust adjusted profile score”. In: *The Annals of Statistics* 48.3
876 (2020), pp. 1742–1769.
- 877 [14] Ruth JF Loos and Tuomas O Kilpeläinen. “Genes that make you fat, but keep you
878 healthy”. In: *Journal of internal medicine* 284.5 (2018), pp. 450–463.
- 879 [15] Christopher N Foley et al. “MR-Clust: clustering of genetic variants in Mendelian
880 randomization with similar causal estimates”. In: *Bioinformatics* 37.4 (2021), pp. 531–
881 541.
- 882 [16] Daniel Iong, Qingyuan Zhao, and Yang Chen. “A latent mixture model for het-
883 erogeneous causal mechanisms in Mendelian randomization”. In: *arXiv preprint
884 arXiv:2007.06476* (2020).
- 885 [17] Nicolas Apfel and Xiaoran Liang. “Agglomerative Hierarchical Clustering for Se-
886 lecting Valid Instrumental Variables”. In: *arXiv preprint arXiv:2101.05774* (2021).
- 887 [18] Alessandra Marengoni et al. “Aging with multimorbidity: a systematic review of
888 the literature”. In: *Ageing research reviews* 10.4 (2011), pp. 430–439.
- 889 [19] Academy of medical sciences (Royaume uni). *Multimorbidity: a priority for global
890 health research*. Academy of medical sciences, 2018.
- 891 [20] Jane AH Masoli, Luke C Pilling, and Timothy M Frayling. “Genomics and multi-
892 morbidity”. In: *Age and Ageing* 51.12 (2022), afac285.

- 893 [21] Verena Zuber et al. “Multi-response Mendelian randomization: Identification of
894 shared and distinct exposures for multimorbidity and multiple related disease out-
895 comes”. In: *The American Journal of Human Genetics* 110.7 (2023), pp. 1177–
896 1199.
- 897 [22] Calypse B Agborsangaya et al. “Multimorbidity prevalence in the general popula-
898 tion: the role of obesity in chronic disease clustering”. In: *BMC Public Health* 13.1
899 (2013), pp. 1–6.
- 900 [23] M Kivimaki et al. “Body-mass index and risk of obesity-related complex multimor-
901 bidity: an observational multicohort study. *Lancet Diabetes Endocrinol.* 2022; 10:
902 253–63”. In: *Article PubMed PubMed Central* (), p. 253.
- 903 [24] Susan Martin et al. “Disease consequences of higher adiposity uncoupled from its ad-
904 verse metabolic effects using Mendelian randomisation”. In: *Elife* 11 (2022), e72452.
- 905 [25] Andrew J Grant et al. “Noise-augmented directional clustering of genetic associ-
906 ation data identifies distinct mechanisms underlying obesity”. In: *PLoS Genetics*
907 18.1 (2022), e1009975.
- 908 [26] Luca Scrucca et al. “mclust 5: clustering, classification and density estimation using
909 Gaussian finite mixture models”. In: *The R journal* 8.1 (2016), p. 289.
- 910 [27] William G Cochran. “The comparison of percentages in matched samples”. In:
911 *Biometrika* 37.3/4 (1950), pp. 256–266.
- 912 [28] Brendan Bulik-Sullivan et al. “An atlas of genetic correlations across human diseases
913 and traits”. In: *Nature genetics* 47.11 (2015), pp. 1236–1241.
- 914 [29] A. Belloni et al. “Sparse Models and Methods for Optimal Instruments With an
915 Application to Eminent Domain”. In: *Econometrica* 80.6 (2012), pp. 2369–2429.
916 DOI: 10.3982/ecta9626.
- 917 [30] Buhm Han and Eleazar Eskin. “Random-effects model aimed at discovering asso-
918 ciations in meta-analysis of genome-wide association studies”. In: *The American*
919 *Journal of Human Genetics* 88.5 (2011), pp. 586–598.
- 920 [31] Jingshu Wang et al. “Causal inference for heritable phenotypic risk factors using
921 heterogeneous genetic instruments”. In: *PLoS genetics* 17.6 (2021), e1009575.
- 922 [32] Kyoko Watanabe et al. “Functional mapping and annotation of genetic associations
923 with FUMA”. In: *Nature communications* 8.1 (2017), p. 1826.
- 924 [33] D John Betteridge. “What is oxidative stress?” In: *Metabolism* 49.2 (2000), pp. 3–8.
- 925 [34] Prasenjit Manna and Sushil K Jain. “Obesity, oxidative stress, adipose tissue dys-
926 function, and the associated health risks: causes and therapeutic strategies”. In:
927 *Metabolic syndrome and related disorders* 13.10 (2015), pp. 423–444.
- 928 [35] Heather K Vincent and Ann G Taylor. “Biomarkers and potential mechanisms of
929 obesity-induced oxidant stress in humans”. In: *International journal of obesity* 30.3
930 (2006), pp. 400–418.
- 931 [36] Taka-aki Matsuoka et al. “Glycation-dependent, reactive oxygen species-mediated
932 suppression of the insulin gene promoter activity in HIT cells.” In: *The Journal of*
933 *clinical investigation* 99.1 (1997), pp. 144–150.

- 934 [37] Shigetada Furukawa et al. “Increased oxidative stress in obesity and its impact
935 on metabolic syndrome”. In: *The Journal of clinical investigation* 114.12 (2017),
936 pp. 1752–1761.
- 937 [38] Panagiotis Lepetsos and Athanasios G Papavassiliou. “ROS/oxidative stress signal-
938 ing in osteoarthritis”. In: *Biochimica et Biophysica Acta (BBA)-Molecular Basis of*
939 *Disease* 1862.4 (2016), pp. 576–591.
- 940 [39] Karol Tejchman, Katarzyna Kotfis, and Jerzy Sieńko. “Biomarkers and mechanisms
941 of oxidative stress—last 20 Years of Research with an emphasis on kidney damage
942 and renal transplantation”. In: *International journal of molecular sciences* 22.15
943 (2021), p. 8010.
- 944 [40] Zhe Lu et al. “Oxidative stress and psychiatric disorders: evidence from the bidi-
945 rectional mendelian randomization study”. In: *Antioxidants* 11.7 (2022), p. 1386.
- 946 [41] Pu Yifu. “Evidence for causal effects of polycystic ovary syndrome on oxidative
947 stress: a two-sample mendelian randomisation study”. In: *BMC Medical Genomics*
948 16.1 (2023), p. 141.
- 949 [42] JD Crapo. “Oxidative stress as an initiator of cytokine release and cell damage”.
950 In: *European Respiratory Journal* 22.44 suppl (2003), 4s–6s.
- 951 [43] K Ito et al. “Oxidative stress reduces histone deacetylase 2 activity and enhances
952 IL-8 gene expression: role of tyrosine nitration”. In: *Biochemical and biophysical*
953 *research communications* 315.1 (2004), pp. 240–245.
- 954 [44] Lars Wallentin et al. “Growth differentiation factor 15, a marker of oxidative stress
955 and inflammation, for risk assessment in patients with atrial fibrillation: insights
956 from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
957 Atrial Fibrillation (ARISTOTLE) trial”. In: *Circulation* 130.21 (2014), pp. 1847–
958 1858.
- 959 [45] Marie Verbanck et al. “Detection of widespread horizontal pleiotropy in causal
960 relationships inferred from Mendelian randomization between complex traits and
961 diseases”. In: *Nature genetics* 50.5 (2018), pp. 693–698.
- 962 [46] Giovanni Davi et al. “Platelet activation in obese women: role of inflammation and
963 oxidant stress”. In: *Jama* 288.16 (2002), pp. 2008–2014.
- 964 [47] Samina Salim. “Oxidative stress and psychological disorders”. In: *Current neu-*
965 *ropharmacology* 12.2 (2014), pp. 140–147.
- 966 [48] Maureen Redza-Dutordoir and Diana A Averill-Bates. “Activation of apoptosis sig-
967 nalling pathways by reactive oxygen species”. In: *Biochimica et Biophysica Acta*
968 *(BBA)-Molecular Cell Research* 1863.12 (2016), pp. 2977–2992.
- 969 [49] James D Johnson and Dan S Luciani. “Mechanisms of pancreatic β -cell apoptosis
970 in diabetes and its therapies”. In: *The Islets of Langerhans* (2010), pp. 447–462.
- 971 [50] Marcello Del Carlo Jr and Richard F Loeser. “Cell death in osteoarthritis”. In:
972 *Current rheumatology reports* 10.1 (2008), pp. 37–42.
- 973 [51] Rodrigo Franco et al. “Oxidative stress, DNA methylation and carcinogenesis”. In:
974 *Cancer letters* 266.1 (2008), pp. 6–11.
- 975 [52] Yingmei Niu et al. “Oxidative stress alters global histone modification and DNA
976 methylation”. In: *Free Radical Biology and Medicine* 82 (2015), pp. 22–28.

- 977 [53] Frances M Ashcroft. *Ion channels and disease*. Academic press, 1999.
- 978 [54] Richard E Ostlund Jr et al. “The ratio of waist-to-hip circumference, plasma insulin
979 level, and glucose intolerance as independent predictors of the HDL2 cholesterol
980 level in older adults”. In: *New England Journal of Medicine* 322.4 (1990), pp. 229–
981 234.
- 982 [55] Rena R Wing et al. “Waist to hip ratio in middle-aged women. Associations with
983 behavioral and psychosocial factors and with changes in cardiovascular risk fac-
984 tors.” In: *Arteriosclerosis and thrombosis: a journal of vascular biology* 11.5 (1991),
985 pp. 1250–1257.
- 986 [56] Gerd Schmitz and Margot Grandl. “The molecular mechanisms of HDL and asso-
987 ciated vesicular trafficking mechanisms to mediate cellular lipid homeostasis”. In:
988 *Arteriosclerosis, thrombosis, and vascular biology* 29.11 (2009), pp. 1718–1722.
- 989 [57] Shao-Nian Yang and Per-Olof Berggren. “The role of voltage-gated calcium channels
990 in pancreatic β -cell physiology and pathophysiology”. In: *Endocrine reviews* 27.6
991 (2006), pp. 621–676.
- 992 [58] Eva Xepapadaki et al. “Impact of apolipoprotein A1-or lecithin: cholesterol acyltransferase-
993 deficiency on white adipose tissue metabolic activity and glucose homeostasis in
994 mice”. In: *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 1865.6
995 (2019), pp. 1351–1360.
- 996 [59] Marie M Gleason, MS Medow, and Thomas N Tulenko. “Excess membrane choles-
997 terol alters calcium movements, cytosolic calcium levels, and membrane fluidity in
998 arterial smooth muscle cells.” In: *Circulation Research* 69.1 (1991), pp. 216–227.
- 999 [60] Eva Xepapadaki et al. “HDL and type 2 diabetes: the chicken or the egg?” In:
1000 *Diabetologia* 64 (2021), pp. 1917–1926.
- 1001 [61] Miriam S Udler et al. “Type 2 diabetes genetic loci informed by multi-trait asso-
1002 ciations point to disease mechanisms and subtypes: a soft clustering analysis”. In:
1003 *PLoS medicine* 15.9 (2018), e1002654.
- 1004 [62] Donald W. K. Andrews. “Consistent Moment Selection Procedures for Generalized
1005 Method of Moments Estimation”. In: *Econometrica* 67.3 (1999), pp. 543–563. DOI:
1006 10.1111/1468-0262.00036.
- 1007 [63] Andrew Khor et al. “Diabetes mellitus is not a risk factor for osteoarthritis”. In:
1008 *RMD open* 6.1 (2020), e001030.
- 1009 [64] Ana Luiza Arruda et al. “Genetic underpinning of the comorbidity between type 2
1010 diabetes and osteoarthritis”. In: *The American Journal of Human Genetics* 110.8
1011 (2023), pp. 1304–1318.
- 1012 [65] Joe H Ward Jr. “Hierarchical grouping to optimize an objective function”. In: *Jour-
1013 nal of the American statistical association* 58.301 (1963), pp. 236–244.
- 1014 [66] William M Rand. “Objective criteria for the evaluation of clustering methods”. In:
1015 *Journal of the American Statistical association* 66.336 (1971), pp. 846–850.
- 1016 [67] Anubha Mahajan et al. “Fine-mapping type 2 diabetes loci to single-variant resolu-
1017 tion using high-density imputation and islet-specific epigenome maps”. In: *Nature
1018 genetics* 50.11 (2018), pp. 1505–1513.
- 1019 [68] FinnGen. *FinnGen Documentation of R8 release*. 2022. URL: [https://finngen.
1020 gitbook.io/documentation/](https://finngen.gitbook.io/documentation/).

- 1021 [69] Martin Kircher et al. “A general framework for estimating the relative pathogenicity
1022 of human genetic variants”. In: *Nature genetics* 46.3 (2014), pp. 310–315.
- 1023 [70] Daifeng Wang et al. “Comprehensive functional genomic resource and integrative
1024 model for the human brain”. In: *Science* 362.6420 (2018), eaat8464.
- 1025 [71] Monique GP Van Der Wijst et al. “Single-cell RNA sequencing identifies celltype-
1026 specific cis-eQTLs and co-expression QTLs”. In: *Nature genetics* 50.4 (2018), pp. 493–
1027 497.
- 1028 [72] Benjamin J Schmiedel et al. “Impact of genetic polymorphisms on human immune
1029 cell gene expression”. In: *Cell* 175.6 (2018), pp. 1701–1715.
- 1030 [73] Urmo Võsa et al. “Unraveling the polygenic architecture of complex traits using
1031 blood eQTL metaanalysis”. In: *BioRxiv* (2018), p. 447367.
- 1032 [74] Elin Grundberg et al. “Mapping cis-and trans-regulatory effects across multiple
1033 tissues in twins”. In: *Nature genetics* 44.10 (2012), pp. 1084–1089.
- 1034 [75] Bernard Ng et al. “An xQTL map integrates the genetic architecture of the hu-
1035 man brain’s transcriptome and epigenome”. In: *Nature neuroscience* 20.10 (2017),
1036 pp. 1418–1426.
- 1037 [76] Menachem Fromer et al. “Gene expression elucidates functional impact of polygenic
1038 risk for schizophrenia”. In: *Nature neuroscience* 19.11 (2016), pp. 1442–1453.
- 1039 [77] Adaikalavan Ramasamy et al. “Genetic variability in the regulation of gene ex-
1040 pression in ten regions of the human brain”. In: *Nature neuroscience* 17.10 (2014),
1041 pp. 1418–1428.
- 1042 [78] GTEx Consortium et al. “The Genotype-Tissue Expression (GTEx) pilot analysis:
1043 multitissue gene regulation in humans”. In: *Science* 348.6235 (2015), pp. 648–660.
- 1044 [79] GTEx Consortium Lead analysts: Aguet François 1 Brown Andrew A. 2 3 4 Castel
1045 Stephane E. 5 6 Davis Joe R. 7 8 He Yuan 9 Jo Brian 10 Mohammadi Pejman 5 6
1046 Park YoSon 11 Parsana Princy 12 Segrè Ayellet V. 1 Strober Benjamin J. 9 Zappala
1047 Zachary 7 8 et al. “Genetic effects on gene expression across human tissues”. In:
1048 *Nature* 550.7675 (2017), pp. 204–213.
- 1049 [80] Arthur Liberzon et al. “Molecular signatures database (MSigDB) 3.0”. In: *Bioin-
1050 formatics* 27.12 (2011), pp. 1739–1740.
- 1051 [81] Martina Kutmon et al. “WikiPathways: capturing the full diversity of pathway
1052 knowledge”. In: *Nucleic acids research* 44.D1 (2016), pp. D488–D494.
- 1053 [82] Jacqueline MacArthur et al. “The new NHGRI-EBI Catalog of published genome-
1054 wide association studies (GWAS Catalog)”. In: *Nucleic acids research* 45.D1 (2017),
1055 pp. D896–D901.
- 1056 [83] Benjamin B Sun et al. “Genomic atlas of the human plasma proteome”. In: *Nature*
1057 558.7708 (2018), pp. 73–79.
- 1058 [84] Alexander Gudjonsson et al. “A genome-wide association study of serum proteins
1059 reveals shared loci with common diseases”. In: *Nature communications* 13.1 (2022),
1060 p. 480.
- 1061 [85] Ari V Ahola-Olli et al. “Genome-wide association study identifies 27 loci influenc-
1062 ing concentrations of circulating cytokines and growth factors”. In: *The American
1063 Journal of Human Genetics* 100.1 (2017), pp. 40–50.

- 1064 [86] Marita Kalaoja et al. “The role of inflammatory cytokines as intermediates in the
1065 pathway from increased adiposity to disease”. In: *Obesity* 29.2 (2021), pp. 428–437.
- 1066 [87] Niamh Mullins et al. “Genome-wide association study of more than 40,000 bipo-
1067 lar disorder cases provides new insights into the underlying biology”. In: *Nature*
1068 *genetics* 53.6 (2021), pp. 817–829.
- 1069 [88] Naomi R Wray, Patrick F Sullivan, et al. “Genome-wide association analyses iden-
1070 tify 44 risk variants and refine the genetic architecture of major depression. bioRxiv”.
1071 In: URL <https://www.biorxiv.org/content/early/2017/07/24/167577> (2017).
- 1072 [89] Dmitry Shungin et al. “New genetic loci link adipose and insulin biology to body
1073 fat distribution”. In: *Nature* 518.7538 (2015), pp. 187–196.
- 1074 [90] “Discovery and refinement of loci associated with lipid levels”. In: *Nature genetics*
1075 45.11 (2013), pp. 1274–1283.
- 1076 [91] “A comprehensive 1000 Genomes–based genome-wide association meta-analysis of
1077 coronary artery disease”. In: *Nature genetics* 47.10 (2015), pp. 1121–1130.
- 1078 [92] Frank Windmeijer et al. “The confidence interval method for selecting valid instru-
1079 mental variables”. In: *Journal of the Royal Statistical Society: Series B (Statistical*
1080 *Methodology)* 83.4 (2021), pp. 752–776.

1081 Funding

1082 This work was supported by the Strategic Priority Fund “Tackling multimorbidity at
1083 scale” programme (grant number MC/MR/WO14548/1) delivered by the Medical Re-
1084 search Council and the National Institute for Health and Care Research in partnership
1085 with the Economic and Social Research Council and in collaboration with the Engineer-
1086 ing and Physical Sciences Research Council. Nicolas Apfel is supported by the ESRC
grant EST013567/1.



Medical
Research
Council



Economic
and Social
Research Council

NIHR | National Institute
for Health Research

1087